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Endogenous Cushing’s syndrome (CS), a rare endocrine disorder characterized by
cortisol hypersecretion, is associated with psychiatric and neurocognitive disorders.
Major depression, mania, anxiety, and neurocognitive impairment are the most important
clinical abnormalities. Moreover, patients most often complain of impairment in quality
of life, interference with family life, social, and work performance. Surprisingly, after
hypercortisolism resolution, despite the improvement of the overall prevalence of
psychiatric and neurocognitive disorders, the brain volume loss at least partially persists
and it should be noted that some patients may still display depression, anxiety, panic
disorders, and neurocognitive impairment. This brief review aimed at describing the
prevalence of psychiatric and neurocognitive disorders and their characterization both
during the active and remission phases of CS. The last section of this review is dedicated
to quality of life, impaired during active CS and only partially resolved after resolution of
hypercortisolism.
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Introduction
Chronic glucocorticoid (GC) overproduction by the adrenal glands represents the cause of endoge-
nous Cushing’s syndrome (CS), a rare but serious endocrine disorder. In approximately 80% of
cases, endogenous CS is consequence of an ACTH hypersecretion (ACTH-dependent CS), gen-
erally due to a corticotroph pituitary tumor (Pituitary-dependent CS, or Cushing’s disease, CD),
and rarely due to an ACTH-secreting or CRH-secreting extra-pituitary tumor (Ectopic Cush-
ing Syndrome, ECS), whereas in the remaining 20% of cases CS is independent from ACTH
hypersecretion (ACTH-independent CS) and GC excess is direct consequence of autonomous
overproduction by the adrenal glands, because of unilateral adrenocortical tumors or bilateral
adrenal hyperplasia, or dysplasia (Arnaldi et al., 2003; Newell-Price et al., 2006; Pivonello et al.,
2008). Chronic endogenous GC exposure determines several clinical complications, including
metabolic complications such as visceral obesity, insulin resistance with glucose intolerance
and diabetes mellitus, and dyslipidemia, which configure a metabolic syndrome, cardiovascular
complications such as systemic arterial hypertension, atherosclerosis, thromboembolism, bone
complications such as osteoporosis and osteoarthritis, infective complications, ranging from an
increase susceptibility to infections up to a fatal sepsis, as well as neuropsychiatric disorders
(Pivonello et al., 2005, 2010; Tauchmanovà et al., 2006; De Leo et al., 2010; Pereira et al.,
2010; van der Pas et al., 2013). These clinical complications negatively impact the quality of
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life (QoL) of patients with CS and increase their morbidity and
mortality, mainly due to cardiovascular and infective diseases
(Gotch, 1994; Webb et al., 2008; Clayton, 2010). The current
management of patients with CS cannot ignore psychiatric and
neurocognitive disorders, their evolution during the active dis-
ease and after disease remission, and their impact on QoL. The
first description of neuropsychiatric disturbances in CS occurred
in 1932 when, in his original description of a series of 12 CS
cases, Harvey Cushing highlighted the presence of “emotional
disturbances” as a pathologic feature of CS (Cushing, 1932). Dur-
ing the following years, several studies were performed with the
purpose to better characterize the spectrum and the frequency
of neuropsychiatric disorders in patients with CS (Sonino and
Fava, 2001). These disorders include psychiatric disorders such
as major depression, mania and anxiety, and neurocognitive
disorders, mainly characterized by impairment of memory and
concentration (Dorn et al., 1997; Sonino and Fava, 2001). Neu-
ropsychiatric disorders contribute to significantly impair health-
related QoL (Gotch, 1994; Webb et al., 2008). The aim of this
brief review was to describe the main psychiatric and neurocog-
nitive disorders observed in patients with endogenous CS during
active disease and their development after disease remission, also
discussing their impact on QoL. Additionally, this brief review
aimed at addressing a simple overview on this topic, highlighting
the important role of long-term follow-up and careful periodi-
cal investigation of psychiatric and neurocognitive disorders in
the management of CS both in the active phase and after disease
remission.
Neuropsychiatric Disorders during Active
Disease
GCs have a crucial role in stress response and GC receptors
have a pleiotropic distribution in central nervous system (CNS),
mainly in the hippocampus; therefore, it is not surprising that
chronic GC excess can lead to structural and functional changes
in CNS, which are mainly based on brain atrophy (De Kloet
et al., 1998; Sonino et al., 2010). The mechanisms by which GCs
induce brain damage are largely unknown although four theo-
ries have been suggested. (1) The decrease of glucose uptake is
responsible of brain atrophy. According with this theory, GCs
induce brain damage by reducing glucose utilization in brain,
as supported by the evidence of a generalized reduction in cere-
bral glucose metabolism in all areas of the brain in patients with
CD. (2) The increase of excitatory aminoacids is responsible of
toxic effects on nervous cells. GCs increase the release or enhance
the effects of excitatory aminoacids, such as glutamate, which
cause cell damage inducing the dendritic atrophy, particularly
in the hippocampus. (3) The inhibition of “long-term potenti-
ation” is responsible of cognitive deficits. GCs reduce the syn-
thesis of neurotrophic factors, such as nerve growth factor-b and
brain-derived neurotrophic factor, which through a presynaptic
mechanism inhibit the long-term potentiation that is believed to
be the mechanism behind learning process and memory forma-
tion. Additionally, this neurotrophic factors reduction can also be
responsible of brain atrophy. (4) The suppression of neurogenesis
in the dentate gyrus. GCs excess may suppress neurogenesis in
the dentate gyrus, which determine hippocampal volume loss
(De Kloet et al., 1998; Jacobs et al., 2000; Simmons et al., 2000;
Bourdeau et al., 2002; Patil et al., 2007; Michaud et al., 2009).
All these mechanisms seem to explain the GC-induced brain
and, mainly, hippocampal damage responsible for neurocogni-
tive disorders, although the atrophy of the prefrontal cortex
(Patil et al., 2007) or the suppression of neurogenesis in the
dentate gyrus (Jacobs et al., 2000) have been specifically identi-
fied as crucial pathophysiological events for the development of
depression.
Themost important psychiatric disorders observed in patients
with active CS are: (1) major depression, which include alter-
ations in mood, affective, vegetative, and cognitive functions; and
(2) mania and anxiety. Major depression represents the most fre-
quent and severe psychiatric disorder associated with chronic
endogenous hypercortisolism. The prevalence of major depres-
sion in patients with CS is reported to be about 50–81%, as sum-
marized in Table 1 (Haskett, 1985; Hudson et al., 1987; Loosen
et al., 1992; Sonino et al., 1993, 1998; Dorn et al., 1995; Kelly,
1996). Focusing on CD, Sonino and co-workers reported major
depression to occur in 54% of 162 patients and observed that it
was significantly associated with female gender, older ages, higher
urinary cortisol levels, relatively more severe clinical conditions
and undetectable pituitary tumor (Sonino et al., 1998). Differ-
ent degrees of severity were reported, ranging from latent to very
severe melanchonic forms, also associated with suicide thoughts
and attempts (Starkman et al., 1981; Starkman, 2013). Therefore,
a careful periodic investigation of psychiatric symptoms should
be performed in all patients with active CS, also taking in consid-
eration that depression in these patients is typically characterized
by intermittent phases, with episodes of exacerbation recurring
very frequently at irregular intervals (Starkman et al., 1981; Stark-
man, 2013). Additionally, all domains of the depressive syndrome
including mood, affect, vegetative, and cognitive functions can be
compromised (Starkman, 2013). As far as mood alterations are
concerned, many patients with CS up to 86%, show irritability,
which often has early onset, appearing even before than other
clinical symptoms and signs (Starkman et al., 1981; Starkman,
2013). It has been reported that patients with CS described them-
selves as having an increased sensitivity and they perceived them-
selves unable to ignore minor irritations and feeling “impatient,”
with “over-reactivity,” generalized hypersensitivity to stimuli and
an easy development of anger (Starkman et al., 1981). Depressed
mood has been reported in 74% of CS patients, without regular
cyclicity, although a common depressive episode persists usually
1–2 days and rarely more than 3 days per week (Starkman, 2013).
In some patients depressed mood could be present on awakening
and remain throughout the day or the next day as well (Stark-
man et al., 1981); in other patients, the onset of depressed mood
occurs suddenly during the day, determining “mood lability”
(Starkman et al., 1981). Moreover, in patients with CS, depressed
mood has been reported to be often characterized by hypersen-
sitivity and oversentimentality, increased feeling of crying, short
spells of sadness, and less frequently constant hopelessness, social
withdrawal with feelings of discomfort in large groups, intermit-
tent inability to experience pleasure, which rarely reaches the
Frontiers in Neuroscience | www.frontiersin.org 2 April 2015 | Volume 9 | Article 129
Pivonello et al. Neuropsychiatric disorders in Cushing’s syndrome
TABLE 1 | Prevalence of major depression in patients with active CS
(adapted from Sonino and Fava, 2001).
References Diagnosis No. of PTS Major depression:
No. of PTS (%)
Sonino et al., 1998 CD 162 88 (54)
Haskett, 1985 All forms 30 24 (80)
Hudson et al., 1987 CD 16 9 (56)
Loosen et al., 1992 CD 20 13 (65)
Sonino et al., 1993 CS excluding CD 20 10 (50)
Kelly, 1996 All forms 209 120 (57)
Dorn et al., 1995 All forms 33 17 (51)
Total 490 281 (57)
CS, Cushing’s syndrome; CD, Cushing’s disease.
levels of persistent anhedonia, and less often self-accusatory or
irrational guilt (Starkman et al., 1981; Starkman, 2013). Con-
versely, a minority of patients, particularly in the first phase of
active hypercortisolism, experiences elevatedmood with episodes
of hyperactivity, increased ambition and restlessness that gener-
ally disappears with the time over disease progression (Starkman
et al., 1981; Starkman, 2013). Suicidal thoughts (17%) and suicide
attempts (5%) have also been described (Starkman et al., 1981;
Starkman, 2013) and frequently minimized by patients (Haskett,
1985; Sonino and Fava, 2001). In patients with active hypercorti-
solism symptoms and signs involving the vegetative functions are
frequently reported. Indeed, fatigue has been described in almost
all patients and a decreased libido in about two-thirds (Stark-
man et al., 1981). Disturbance of appetite and sleep have also
been described; particularly, an increased or decreased appetite
have been found in about 34% and 20% of patients, respectively
(Starkman et al., 1981) and sleep disturbances such as middle
insomnia (patients awakened at least one during the night) in
69% of CS patients, late insomnia (patients awakened earlier than
desired in the morning) in 57% and early insomnia (inability to
fall asleep at bedtime) in 29% (Starkman et al., 1981; Starkman,
2013). In about one third of patients, it has also been reported
an alteration in the frequency and type of dreams which became
more bizarre and vivid (Starkman et al., 1981; Starkman, 2013).
Within the clinical frame of depressive syndrome, patients may
also experience cognitive impairments that will be detailed below.
A significant percentage (66%) of CS patients reported gener-
alized anxiety or panic disorders more frequently described in the
chronic and advanced stage of active hypercortisolism (Starkman
et al., 1981; Starkman, 2013). Also bipolar disorders including
maniac and hypomaniac episodes have been observed in about
30% of CS patients and may represent an early manifestation of
CS (Haskett, 1985; Hudson et al., 1987).
Neurocognitive impairment has been reported in about two
thirds of CS patients with variable degrees from mild to severe
(Whelan et al., 1980). An impairment of memory has been
reported in 83% of CS patients, consisting of difficulty in pro-
cessing new information and forgetfulness of information such
as appointments, names of people, location of objects, impor-
tant dates in their personal, and/or medical histories (Starkman
et al., 1981; Starkman, 2013). Impaired concentration has been
reported in 66% of CS patients that particularly complain of
mind-wandering when reading, watching television and during
the course of conversations, a decreased ability to “focus their
minds” and more in general inattention, distractibility, short-
ened attention span, difficulties with reasoning ability, and com-
prehension (Starkman et al., 1981; Starkman, 2013). Moreover,
disturbances in “thinking” may occur. Indeed, patients with CS
can experience episodes of rapid and scattered thinking, or slow
thinking with blocks, that are described as a mind, which sud-
denly “becomes blank” (Starkman, 2013). In addition, impair-
ment in verbal control, non-verbal, visual, and spatial abilities has
also been reported in CS patients (Starkman et al., 1981; Sonino
and Fava, 2001; Starkman, 2013).
Neuropsychiatric Disorders after Disease
Remission
Several studies have reported that, after disease remission, the
resolution of hypercortisolism, namely the normalization of cor-
tisol secretion, is not constantly followed by the complete recov-
ery of many clinical complications developed during the active
disease; in particular, metabolic syndrome and the consequent
cardiovascular risk have been found to partially persist after dis-
ease remission (Colao et al., 1999; Faggiano et al., 2003; Pivonello
et al., 2005, 2007). Skeletal diseases, mainly osteoporosis, improve
after disease remission, but the normalization of bone mass
may require a long period of time or the use of specific treat-
ments (Faggiano et al., 2001; Pivonello et al., 2007). Similarly,
psychiatric and neurocognitive disorders generally improve after
disease remission, but several studies reported that these disor-
ders can persist, even long-term after the resolution of hyper-
cortisolism and occasionally they can even exacerbate with the
decrease and resolution of hypercortisolism. Consequently, this
slow and partial recovery of different clinical alterations occurred
during the active phase of the disease can contribute to the per-
sistent impairment of QoL registered in CS patients after disease
remission or cure (Sonino and Fava, 2001; Pivonello et al., 2007;
Webb et al., 2008; Colao et al., 2012).
To date, the issue of whether remission of CS may completely
resolve psychiatric and neurocognitive disorders remains con-
troversial. Several studies demonstrated a significant improve-
ment of psychiatric and neurocognitive disorders after resolution
of hypercortisolism (Jeffcoate et al., 1979; Cohen, 1980; Kram-
linger et al., 1985; Starkman et al., 1986; van der Lely et al.,
1991; Verhelst et al., 1991; Kelly et al., 1996; Wolkowitz and
Reus, 1999; Hirsch et al., 2000). In particular, Starkman and co-
workers reported a significant improvement in depression scores
of patients treated for CD, which were significantly correlated
with the decrease in urinary cortisol excretion (Starkman et al.,
1986). Different studies described significant improvements or
even complete remission of depression, anxiety, irritability, psy-
chosis, and neurocognitive impairment, after normalization of
cortisol levels in CS patients treated with radiotherapy, surgery,
or medical treatment (Jeffcoate et al., 1979; Cohen, 1980; Kram-
linger et al., 1985; Starkman et al., 1986; van der Lely et al.,
1991; Verhelst et al., 1991; Kelly et al., 1996; Dorn et al., 1997;
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Wolkowitz and Reus, 1999; Hirsch et al., 2000). Particularly,
some studies have reported the effects of successful reduction
of GCs excess on psychopathology. These studies demonstrate
that both reduction of GCs synthesis with ketoconazole or
metyrapone and blockade of the GC receptor with mifepristone
positively affect psychopathology. Interestingly, mifepristione
has been demonstrated to have therapeutic effects in patients
with psychotic depression. Additionally, this drug can mitigate
the weight gain associated with the use of antipsychotic drugs
and improve cognitive dysfunction in bipolar depression (How-
land, 2013). However, as mentioned above, more recently, sev-
eral studies showed that neuropsychiatric improvement, after a
successful treatment of CS, might be delayed and incomplete
(Dorn and Cerrone, 2000; Sonino and Fava, 2001; Forget et al.,
2002; Heald et al., 2004; Merke et al., 2005; Maheu et al., 2008;
Tiemensma et al., 2010; Ragnarsson et al., 2012; Resmini et al.,
2012; Ragnarsson and Johannsson, 2013). Indeed, both psy-
chiatric and neurocognitive alterations may require long time
to recover after remission of hypercortisolism and they may
sometimes persist even after CS cure. Long-lasting impairments
were reported in many domains of cognitive function includ-
ing attention, visuospatial orienting, alerting, reasoning, work-
ing and speed memory, verbal fluency, reading, and executive
functions (Forget et al., 2002; Tiemensma et al., 2010; Ragnars-
son et al., 2012; Resmini et al., 2012). Indeed, the brain volume
loss, which is considered the main responsible for the neurocog-
nitive decline of active CS patients, has been demonstrated to
be partially persistent after remission (Bourdeau et al., 2002),
but further studies are still required to determine whether these
alterations can fully revert after long-term remission or bet-
ter after a time long enough to consider the patients defini-
tively cured. Additionally, in patients long-term remitted from
CS, proton magnetic resonance spectroscopy, measuring brain
metabolites in the hippocampus, suggested neuronal dysfunction
or loss and consequently a repair mechanism of glial prolifera-
tion (Resmini et al., 2013). These alterations indicated the per-
sistence of a neuronal damage associated with negative effects
on hippocampal volume and memory (Resmini et al., 2013).
To investigate whether neuropsychiatric disorders may persist
in all patients treated for pituitary tumors, regardless the type
of hormone secretion, Heald and co-workers compared patients
treated for CD with patients treated for acromegaly, macropro-
lactinomas, or non-functioning pituitary tumors. In this study
patients treated for CD appeared to perceive themselves as being
more depressed, fatigued, anxious, having poorer physical health
and environmental, and social adjustment, showing significantly
impaired psychological well-being and psychosocial function-
ing compared with all other pituitary tumors patients (Heald
et al., 2004). All these observations seem to validate that CS,
even after resolution of hypercortisolism, has long-lasting adverse
effects on CNS, suggesting that depression, anxiety, and neu-
rocognitive impairment, may still dominate the clinical picture
even after disease remission. Interestingly, Dorn and co-workers
firstly reported that in CS patients some psychiatric symptoms
might also exacerbate with cortisol decrease (Dorn et al., 1997).
Particularly, it has been reported that the frequency of panic
attacks and suicidal ideation increased after CS remission in
a subgroup of patients. This phenomenon has been suggested
to be due to the relative GC deficiency, which seems to allow
unrestrained increase in catecholamines (Dorn et al., 1997).
Moreover, in children and adolescents with CS, Merke and
co-workers reported a significant decline of cognitive function
1 year after surgical correction of hypercortisolism, despite a
rapid resolution of cerebral atrophy was observed (Merke et al.,
2005).
Overall these data highlight the importance of a long-term
follow-up and careful periodic investigation of neuropsychi-
atric symptoms in patients with CS also after hypercortisolism
resolution, and the importance to consider the management
of these disorders as one of the essential outcomes of CS
patients.
Effects of Neuropsychiatric Disorders on
Quality of Life
Considering the systemic and neuropsychiatric complications
associated with hypercortisolism it is expected that CS patients
have impairment in QoL (Colao et al., 2012). Indeed, impair-
ment in QoL has been demonstrated both by generic and disease-
specific questionnaires, namely Cushing QoL, which has been
reported to be the most appropriate to measure QoL in patients
with CS (Webb et al., 2008). Multiple physical and psycho-
logical factors can interfere with QoL in CS patients, but the
results of the ERCUSYN study, a recent published web-based,
multicentre, observational study from 23 European countries,
showed that only depression resulted an independent predic-
tor of a lower CS QoL score, suggesting that psychiatric disor-
ders, and mainly depression, may play a pivotal role in affecting
QoL in patients with CS (Valassi et al., 2011). Indeed, patients
suffering from CS most often complain of changes in physi-
cal appearance, depression, emotional instability, fatigue and/or
weakness, sleeping difficulties, neurocognitive problems, inter-
ference with family life, relations with their partner, and with
school/work performance (Gotch, 1994; Colao et al., 2012). As
main psychiatric and neurocognitive disorders, the impairment
in QoL of patients with CS is only partially resolved after treat-
ment of hypercortisolism and a longer-term follow-up showed
that a residual impairment of QoL may persist after long-term
disease remission (Lindsay et al., 2006; Wagenmakers et al.,
2012). Indeed, patients in remission upon proper treatment for
CS displayed significantly higher scores in depression (feeling
tired, guilty, hopeless, unworthy, poor appetite, loss of interest),
anxiety (being nervous, tense, panicky, difficulties falling asleep,
or early morning awakening), and psychotic symptoms (feel-
ings of persecution, delusions, hallucinations), with a general-
ized compromised QoL compared with healthy subjects (Sonino
et al., 2006). Particularly in patients with CD, despite long-
term remission, QoL appeared reduced compared with reference
values from the literature, especially in the presence of pitu-
itary insufficiencies (van Aken et al., 2005). Interestingly, also in
children and adolescents, CS is associated with impaired QoL,
with residual impairment 1-year after treatment, suggesting that
QoL is another important parameter of outcome also in these
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patients and that the identification of factors that contribute to
impair QoL may help to diminish the physical and psychologi-
cal burden of disease in this population of patients (Keil et al.,
2009).
Conclusions
In conclusion, CS is frequently associated with an high preva-
lence of psychiatric and neurocognitive disorders and with a
significant impairment in QoL. Major depression represents
the most important and life-threatening psychiatric complica-
tion, occurring in approximately 50–60% of patients, but mania
and anxiety are also reported in many cases. Additionally,
neurocognitive disorders may occur both as a manifestation
within the depressive syndrome clinical frame, and separately
as isolated neurological disorder. It should be highlighted that
psychiatric and mainly neurocognitive disorders, even long-term
after CS remission, although generally improve, may persist, or
even worsen, contributing to the persistent impairment of QoL
registered also in patients treated for CS. Therefore, long-term
follow-up and careful periodical investigation of psychiatric and
neurocognitive symptoms should be always considered in the
management of CS both in the active phase and after disease
remission.
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